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ABSTRACT
Objectives  Tolerogenic dendritic cells (tolDCs) 
constitute a promising experimental treatment for 
targeting autoreactive T cells in autoimmune diseases, 
including rheumatoid arthritis (RA). The authors’ goal 
is to bring tolDC therapy for RA to the clinic. Here the 
authors address key translational issues related to the 
manufacturing of tolDCs from RA patients with current 
good manufacturing practice (cGMP)-compliant reagents, 
the stability of tolDCs, and the selection of suitable quality 
control markers.
Methods  Human monocyte-derived tolDCs were 
established from RA patients and healthy controls (HCs) 
using the immunosuppressive drugs dexamethasone 
and vitamin D3, and the cGMP-grade immunomodulator, 
monophosphoryl lipid A, in the cGMP-compliant medium, 
CellGroDC. The functionality of tolDCs and tolDC-
modulated autologous CD4 T cells was determined by 
ﬂ  ow cytometry, [3H]thymidine incorporation and ELISA.
Results  Clinical-grade tolDCs established from patients 
with RA exhibit a typical tolerogenic phenotype of 
reduced costimulatory molecules, low production of 
proinﬂ  ammatory cytokines and impaired stimulation of 
autologous antigen-speciﬁ  c T cells, comparable to HC 
tolDCs. Toll-like receptor 2 (TLR-2) was highly expressed 
by tolDCs but not mature DCs. Furthermore, tolDCs 
suppressed mature DC-induced T cell proliferation, 
interferon γ and interleukin 17 production, and rendered 
T cells hyporesponsive to further stimulation. Importantly, 
tolDCs were phenotypically stable in the absence of 
immunosuppressive drugs and were refractory to further 
challenge with proinﬂ  ammatory mediators.
Conclusions  tolDCs established from patients with RA 
are comparable to those derived from healthy donors. 
TLR-2 was identiﬁ  ed as an ideal marker for quality control 
of tolDCs. Potently tolerogenic and highly stable, these 
tolDCs are a promising cellular therapeutic for tailored 
immunomodulation in the treatment of RA.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, debilitat-
ing autoimmune disease with no known cure. 
Autoimmune diseases including RA are thought 
to arise through a breakdown in self-tolerance. 
Current treatments involve non-antigen-speciﬁ  c 
global immunosuppression leading to numerous 
side effects. Much research has therefore focused 
on the development of more selective immuno-
suppressive, drug-sparing therapies with fewer 
complications and the potential of long-term 
  disease remission. T cell immunomodulation, or 
immune reprogramming, is an attractive strategy 
for treatment of autoimmune disorders,1 and a 
novel approach for targeting autoreactive T cells is 
the use of antigen-speciﬁ  c dendritic cells (DCs).2
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DCs are critical in the initiation of immune 
responses against invading pathogens and tumours, 
but also in the induction of central and periph-
eral tolerance to self-antigens.3 The constitutive 
depletion of DCs in mice leads to a collapse in 
self-  tolerance and the development of fatal autoim-
mune disease.4 Tolerogenic DCs (tolDCs) induce 
tolerance through the presentation of antigen with 
inadequate costimulation and cytokine produc-
tion for effector T cell activation, resulting in T cell 
silencing or deletion or induction of regulatory 
T cells.5 6
tolDCs can be generated in vitro by a variety 
of methods, including genetic or pharmacological 
modiﬁ  cation.7 Injection of ex vivo modiﬁ  ed tolDCs 
has proven beneﬁ   cial in models of autoimmune 
disease, including collagen-induced arthritis,8–18 
diabetes,19 experimental autoimmune encephalo-
myelitis16 and uveoretinitis.20 Therapy with 
tolDCs therefore has great potential for the treat-
ment of autoimmunity in humans, and the current 
challenge is to develop tolDCs for clinical applica-
tion. Others have addressed the development of 
clinical-grade DCs for cancer immunotherapy.21–23 
However, criteria for the development of safe 
tolDCs for the treatment of autoimmune disease 
remain to be evaluated.
Previously, we have described a simple and 
robust method for the establishment of tolDCs 
by treatment of monocyte-derived DCs with 
the immunosuppressive glucocorticoid, dexa-
methasone (Dex), the vitamin D receptor agonist, 
1,25(OH)2D3 (vitamin D3 (VitD3)) and the toll-like 
receptor 4 (TLR-4) ligand, lipopolysaccharide (LPS) 
from Escherichia coli.24 25 These tolDCs, character-
ised by low expression of costimulatory molecules 
and low production of proinﬂ  ammatory cytokines, 
have impaired T cell stimulatory capacity and 
tolerise T cells in vitro. Our aim is to conduct clini-
cal trials with these tolDCs for RA.5 26 27
Here we address several key translational issues 
pertaining to clinical application of tolDCs. Firstly, 
research-grade reagents—for example, fetal bovine 
serum or LPS—need to be substituted for current 
good manufacturing practice (cGMP)-compatible 
reagents, without compromising the T cell- tolerising 
effects of tolDCs. Furthermore, monocyte-derived 
DCs are more proinﬂ  ammatory in RA,28 29 there-
fore our protocol requires validation to guaran-
tee generation of effective tolDCs from patients 
with RA. Another important consideration is the 
selection of reliable and easy-to-measure quality 
control (QC) markers. QC markers should ideally 
be highly expressed,30 31 exclusively by tolDCs, 
rather than reliant on comparative expression with 
mature immunogenic DCs. Finally, as tolDCs will 
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be used to treat RA, a chronic inﬂ  ammatory disease, their stabil-
ity in proinﬂ  ammatory environments is paramount and requires 
investigation. This study describes a cGMP-compatible method 
for generating stable tolDCs from patients with RA, resulting in 
a novel autologous cellular therapy for the speciﬁ  c modulation 
of autoreactive T cells for the treatment of RA.
MATERIALS AND METHODS
Ethics
Peripheral blood samples from healthy controls (HCs) and 
patients with RA were obtained with informed consent and 
after approval by the Newcastle and North Tyneside Research 
Ethics Committee 2.
Isolation of cells
Peripheral blood mononuclear cells were isolated by density cen-
trifugation. Monocytes were positively selected from peripheral 
blood mononuclear cells using anti-CD14 microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany). CD4 T cells were enriched 
using CD4 RosetteSep (StemCell, Vancouver, BC, Canada) or by 
positive selection with anti-CD4 microbeads (Miltenyi Biotec).
Establishment of DCs
Monocytes were cultured at 0.5×106/ml for 7 days in cGMP-grade 
CellGroDC (CellGenix, Freiburg, Germany) containing penicil-
lin and streptomycin solution (100 U/ml and 100 μg/ml, respec-
tively) in the presence of clinical-grade granulocyte–macrophage 
colony-stimulating factor (50 ng/ml; Berlex, Seattle, Washington, 
USA) and interleukin 4 (IL-4; 50 ng/ml; Immunotools, Friesoythe, 
Germany). Cells were replenished on day 3 with fresh medium 
and cytokines, and cytokines only on day 6. To induce mature 
DCs (matDCs), DCs were treated with cGMP-grade monophos-
phoryl lipid A (MPLA) (1.0 μg/ml; Avanti Polar Lipids, Alabaster, 
Alabama, USA) on day 6. tolDCs were established by treatment 
with Dex (1 μM, Sigma Aldrich, Poole, UK) on day 3 and Dex 
(1 μM) and VitD3 (0.1 nM, Biomol, Exeter, UK) and MPLA on 
day 6. On day 7, DCs were harvested and washed extensively 
before functional assays were performed. DCs were loaded 
during the ﬁ  nal 24 h of culture with the recall protein antigen, 
puriﬁ  ed protein derivative (PPD; 1 μg/ml; Statens Serum Institut, 
Copenhagen, Denmark), or candidate RA   autoantigen human 
cartilage glycoprotein 39 (HCgp39; 10 μg/ml; Organon , Welwyn 
Garden City, UK). Control DCs were left unloaded. For superan-
tigen experiments, DCs were pulsed with 5 ng/ml toxic shock 
syndrome toxin 1 (TSST-1) for 1 h.
DC phenotyping
Cell surface expression was investigated using the following 
antibodies: CD14-PE (M5E2), CD40-APC (5C3), CD80-FITC 
(L307.4), CD86-APC (FUN-1), CD83-PE (HB15e), HLA-DR DP 
DQ-FITC (Tu39), all from BD Biosciences (Oxford, UK), and 
TLR-2-APC (TL2.1; e-Bioscience, Hatﬁ   eld, UK). DCs were 
washed and resuspended in staining buffer (phosphate-buffered 
saline supplemented with 1% fetal calf serum, 2 mM EDTA 
and 0.01% sodium azide) in the presence of IgG (Grifols, Los 
Angeles, California, USA), and incubated with antibody for 30 
min before acquisition on a BD FACScan and analysed using 
FlowJo software (Treestar).
DC cytokine production
DCs were stimulated at 1×105 DCs/ml with CD40-ligand-
transfected J558L mouse cells (a gift from Professor Peter 
Lane, Birmingham University, UK) at a 1:1 ratio for 24 h. 
Cytokine production was determined in supernatants by 
sandwich ELISA from BD Pharmingen (Oxford, UK) (IL-6, 
IL-10, IL-12p70, tumour necrosis factor (TNF)α) or e-Biosci-
ence (IL-1β, IL-23).
DC/T cell cultures
DC/T cell cultures were carried out in complete medium: RPMI-
1640 containing human AB+ serum (5%), L-glutamine (2 mM), 
and penicillin (100 U/ml) and streptomycin (100 μg/ml). T cells 
(105) were cultured with unloaded or antigen-loaded tolDCs or 
matDCs. In restimulation experiments, primed T cells were sub-
sequently rested from day 6 to 10 in the presence of 20 IU/ml 
recombinant IL-2 (Novartis , Camberley, UK) and restimulated 
on day 10 with antigen-loaded autologous matDCs for 3 days. 
DC/T cell cultures were performed at varying ratios. Proliferation 
was determined by incorporation of [3H]thymidine for 18 h or 
by carboxyﬂ  uorescein succinimidyl ester (0.5 μM) dilution anal-
ysis of T cell receptor β-chain variable region 2 (Vβ2)-expressing 
cells (anti-TCR-Vβ2; clone MPB2D5; Immunotech, Marseille, 
France) at various time points. For the tolDC-suppression assay, 
additional tolDCs or matDCs were incorporated as indicated. 
Cytokine production in T cell supernatants was determined by 
sandwich ELISA for interferon γ (IFNγ) (BD Pharmingen) and 
IL-17 (e-Bioscience).
Intracellular cytokine staining
T cells restimulated with matDCs for 3 days were activated for 
maximal cytokine production with phorbol myristate acetate 
(50 ng/ml) and ionomycin (1 μg/ml) for 5 h in the presence of 
brefeldin A (10 μg/ml) for the ﬁ  nal 4 h. Cells were stained for 
cell surface Vβ2 expression before ﬁ  xation and permeabilisation 
(FoxP3 staining kit; e-Bioscience) and subsequent staining for 
intracellular IL-17 (clone eBio64DEC17) and IFNγ (clone B27). 
Cells were acquired on a BD LSRII and analysed using FlowJo 
software.
DC stability
Phenotypic stability of DCs was investigated 24 h after washing 
and reculture of DCs in complete medium. Firstly, 1×106 cells/
ml were left unstimulated or stimulated with a cocktail of proin-
ﬂ  ammatory cytokines containing 1000 U/ml IFNγ and 10 ng/
ml each of IL-1β, IL-6 and TNFα, 0.1 μg/ml LPS or 10 μg/ml 
peptidoglycan (PGN). Cells were stained as described for DC 
phenotyping, and cytokine production was investigated in the 
absence and presence of proinﬂ   ammatory cytokines, LPS or 
PGN as described for DC cytokine production.
Statistical analysis
The following statistical analyses were performed using Prism 
4.0: analysis of variance (ANOVA) for comparisons between 
multiple groups, Mann–Whitney U or Student t test for compar-
isons between two groups, and two-way ANOVA for multiple 
groups over time.
RESULTS
cGMP-tolDCs from patients with RA are phenotypically and 
functionally comparable to HC tolDCs
Our initial studies investigated the surface phenotype, cytokine 
proﬁ   le and T cell-stimulatory capacity of tolDCs from RA 
patients as compared with HCs, established using the cGMP-
medium CellGroDC and bacterial immunomodulator MPLA. 
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matDCs (ﬁ   gure 1B). A highly expressed marker on tolDCs 
was TLR-2, which was low on iDCs and matDCs (ﬁ  gure 1A,B) 
and may therefore be   suitable for QC. Despite the high pro-
pensity of RA-matDCs to produce TNFα, production of all 
other cytokines investigated was comparable between RA and 
HC cultures (ﬁ  gure 2A). tolDCs from both RA patients and 
HCs consistently produced lower levels of proinﬂ  ammatory 
cytokines IL-1β, IL-6, IL-23 and TNFα upon CD40-mediated 
Immature DCs (iDCs; ﬁ  gure 1A) expressed reduced levels of 
major histocompatibility complex II (MHC II) and low lev-
els of CD40, CD83 and the costimulatory molecules CD80 
and CD86. Expression of all these markers was substantially 
enhanced upon DC maturation (matDCs; ﬁ  gure 1A,B). In con-
trast, tolDCs from both RA patients and HCs displayed a typi-
cal semimature phenotype of reduced MHC II and CD80 and 
signiﬁ  cantly lower CD40, CD83 and CD86 expression than 
Figure 1  Rheumatoid arthritis (RA)-derived tolerogenic dendritic cells (tolDCs) exhibit a semimature phenotype and are comparable to healthy 
control (HC) tolDCs. (A) HC- and RA-derived DC expression of maturation-associated markers of immature DCs (iDCs), mature DCs (matDCs) and 
tolDCs. Histograms are representative of ﬁ  ve independent donors. (B) Mean expression of HC and RA patient tolDCs and matDCs is shown relative 
to iDCs. Expression of each marker (geometric mean ﬂ  uorescence intensity (GMFI)) was normalised relative to expression by iDCs (100%) for each 
independent donor. Phenotypic analysis of maturation-associated markers was determined 24 h after maturation with 1 μg/ml monophosphoryl lipid 
A in the presence or absence of dexamethasone and vitamin D3. Data are expressed as the mean±SEM for ﬁ  ve independent donors. Mean GMFI for 
HC iDCs vs RA iDCs are: MHC II, 949.8±161.3 vs 1110±178.3; CD40, 19.8±7.4 vs 20.4±6.6; CD80, 12.3±1.7 vs 11.2±1.4; CD83, 7.9±0.1 vs 
9.4±1.2; CD86, 11.5±2.5 vs 21.6±5.8; toll-like receptor 2 (TLR-2), 89.9±11.1 vs 76.2±4.2. No signiﬁ  cant difference was detected between RA and 
HC DC populations. *p≤0.05, **p≤0.01, ***p≤0.001 (analysis of variance). MHC, major histocompatibility complex; TLR-2, toll-like receptor-2.
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activation, as compared with matDCs, while IL-12 was nota-
bly undetected in all tolDC cultures (ﬁ  gure 2A). Similar differ-
ences were found when cytokine production by tolDCs and 
matDCs was measured directly after maturation with MPLA, 
before activation through CD40 (online supplemental ﬁ  gure 1). 
Anti-inﬂ  ammatory IL-10 production by tolDCs was non-sig-
niﬁ  cantly reduced as compared with their equivalent matDC 
counterparts.
The cytokine proﬁ  le of tolDCs was unaffected by  incorporation 
of an antigen-loading step during tolDC generation, investi-
gated using a RA candidate autoantigen (HCgp39;   ﬁ  gure 2B). 
Furthermore, we investigated the autologous T cell immuno-
stimulatory capacity of tolDCs using the recall antigen, PPD. 
Minimal T cell proliferation was observed in response to both RA 
and HC non-antigen-loaded DC populations, while PPD-loaded 
matDCs induced signiﬁ  cant T cell proliferation. Consistent with 
their semimature phenotype and   anti-  inﬂ  ammatory  cytokine 
proﬁ  le, both RA and HC PPD-loaded tolDCs only poorly induced 
antigen-speciﬁ  c proliferation (ﬁ  gure 3A,B) and IFNγ and IL-17 
production by autologous T cells (ﬁ  gure 3B).
tolDCs induce T cell hyporesponsiveness
We further investigated the immunoregulatory capacity of 
clinical-grade tolDCs in a superantigen-based T cell activation 
model. This model is well established for studying T cell acti-
vation and modulation by autologous DCs.32–36 TSST-1 binds 
with high afﬁ  nity to TCR-Vβ2, preferentially expanding Vβ2+ 
T cells in a MHC II-dependent manner,37 although expansion 
of low-afﬁ  nity Vβ2− T cells can occur.32 Here we quantitated 
the T cell response to tolDCs and matDCs loaded with TSST-1 
(  ﬁ  gure 4A). matDCs were superior over tolDCs in inducing 
T cell proliferation, inducing activation of Vβ2+ T cells even at 
Figure 2  Healthy control (HC) and rheumatoid arthritis (RA) tolerogenic dendritic cells (tolDCs) have an anti-inﬂ  ammatory phenotpye. (A) Mean 
cytokine production by tolDCs and mature DCs (matDCs) in response to CD40 activation. At 24 h after maturation with 1 μg/ml monophosphoryl lipid 
A (MPLA) in the presence or absence of dexamethasone (Dex) and vitamin D3 (VitD3), DCs were washed, and 105 tolDCs or matDCs cocultured at 
a 1:1 ratio with the J588L-CD40L-expressing cell line in the absence of Dex and VitD3 for a further 24 h. Supernatants were harvested for cytokine 
analysis by ELISA. Data are expressed as the mean±SEM for at least four HCs and seven RA-independent donors. (B) Representative RA donor 
DC-derived cytokine production when unloaded (UL) or loaded with 10 μg/ml human cartilage glycoprotein 39 (HCgp39) as a model antigen, during 
maturation with 1 μg/ml MPLA. Unloaded and antigen-loaded DCs were activated via CD40 as described in (A). Data are representative of four 
independent donors. Cytokine production was determined by ELISA. <d, below limits of detection. Detection limit for IL-12 is 30 pg/ml. *p≤0.05, 
**p≤0.01, ***p≤0.001 (Mann–Whitney U test). TNF, tumour necrosis factor.
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very low DC numbers and also inducing expansion of Vβ2− T 
cells at higher DC numbers. In contrast, tolDCs expanded Vβ2+ 
T cells at high DC concentrations, but failed to support strong 
Vβ2− T cell proliferation (ﬁ  gure 4A). Upon optimal restimula-
tion with TSST-1-loaded matDCs, T cells primed by TSST-1-
loaded tolDCs (Ttol) showed impaired proliferative potential 
(ﬁ   gure 4B) and a reduction in the percentage of IFNγ- and 
IL-17-producing T cells as compared with T cells primed by 
TSST-1-loaded matDCs (Tmat) (ﬁ  gure 4C), suggestive of Ttol 
hyporesponsiveness.
tolDCs suppress matDC-induced T cell proliferation, 
IFNγ and IL-17
Successful tolDC therapy may in part depend on the ability 
to suppress immune responses induced by resident immuno-
genic DCs. We therefore investigated the ability of tolDCs to 
modulate matDC-induced PPD-speciﬁ  c T cell proliferation and 
cytokine production. Co-incubation of PPD-loaded tolDCs and 
matDCs signiﬁ  cantly inhibited T cell proliferation (ﬁ  gure 5A), 
IFNγ and IL-17 production (ﬁ  gure 5B) at a 1:1 tolDC/matDC 
ratio and signiﬁ  cantly inhibited proliferation (ﬁ  gure 5A) and 
IFNγ production at a 1:10 tolDC/matDC ratio (ﬁ  gure 5B) as 
compared with PPD-loaded matDCs alone. These inhibitory 
effects were not caused by increasing the total DC number, as 
doubling the number of matDCs did not result in suppression 
of T cell proliferation and even enhanced cytokine production 
(ﬁ  gure 5A,B).
tolDCs have a highly stable semimature, 
anti-inﬂ  ammatory phenotype
A key consideration in the development of a tolDC therapy 
for RA and other chronic inﬂ  ammatory diseases is the stability 
of tolDCs to proinﬂ  ammatory mediators. tolDC stability was 
therefore investigated after removal of Dex, VitD3 and MPLA 
and reculture in medium containing human serum. Both tolDCs 
and matDCs were phenotypically refractory to stimulation 
with all proinﬂ  ammatory mediators investigated, with tolDCs 
  retaining their typical semimature phenotype and cytokine 
  proﬁ  le (ﬁ  gure 6A,B). TLR-2 expression by tolDCs was found 
to be   downregulated comparable to that of matDC expression   
(ﬁ  gure 6A), while the only marker that was signiﬁ  cantly upreg-
ulated by tolDCs was CD83 in response to   proinﬂ  ammatory 
  cytokines, although levels remained signiﬁ  cantly  (p<0.01; 
paired t test) lower than that expressed by equivalent matDCs 
(ﬁ  gure 6A). CD40-activation-induced cytokine production by 
tolDCs and matDCs was unaltered in response to cytokine or 
LPS challenge (ﬁ  gure 6B), while PGN induced increases in IL-10 
production by both tolDCs and matDCs. IL-12p70 remained 
undetectable in tolDC cultures under all conditions investigated 
(ﬁ  gure 6B). Overall, these data indicate that tolDCs are highly 
stable.
DISCUSSION
This study describes the development of clinical-grade tolDCs, 
focusing on a number of key translational issues that require elu-
cidation before therapeutic application of these cells.
We investigated the functionality of tolDCs generated 
using cGMP-grade reagents, suitable for the development of 
an Investigational Medical Product for human therapy. We 
describe a protocol for the establishment of semimature, anti-
inﬂ  ammatory, clinical-grade tolDCs using the cGMP-compliant 
serum-free medium CellGroDC and DC immunomodulator, 
MPLA. These clinical-grade tolDCs are comparable to our pre-
viously characterised research-grade tolDCs24 25 in terms of 
cell surface phenotype, cytokine production and in vitro T cell 
modulatory function. CellGroDC was deemed the medium of 
choice23 and is currently used in DC vaccine development for 
cancer.38–40 MPLA, a low-toxicity alternative to LPS, is currently 
being tested in vaccine development.41 As a known TLR-4 ago-
nist inducing matDCs,42 MPLA is less potent than LPS,43 which 
may explain the increased MPLA dose (1.0 μg/ml MPLA vs 0.1 
μg/ml LPS25) required to induce comparable DC maturation.42–44 
We observed that MPLA potently induces IL-10 production by 
DCs. Considering the inhibitory effect of IL-10 on IL-12p35 and 
p40 mRNA45 46 and IL-12p40 protein,46 it is not surprising that 
MPLA only poorly induced IL-12p70 and IL-23 (consisting of 
IL-12p40 and IL-23p19) by matDCs in this study. As the lack of 
IL-12 production by tolDCs is pivotal to their tolerogenicity,24 47 
MPLA by virtue of its inability to induce IL-12 is highly appro-
priate for the establishment of tolDCs, but less suitable for the 
generation of matDC therapy for cancer.
As antigen-presenting cell dysregulation has been implicated 
in RA pathogenesis,48 we conﬁ  rmed that this protocol could be 
used for the establishment of tolDCs from patients with RA. 
Indeed, in our and other studies,28 29 matDCs established from 
patients with active RA produced signiﬁ  cantly more TNFα than 
HCs or RA patients in remission. We demonstrate that, despite 
an inherently more proinﬂ  ammatory cytokine proﬁ  le, tolDCs 
established from RA patients adopt a HC-tolDC-like phenotype, 
suggesting that, even with potentially altered antigen-presenting 
cell functionality during RA, it remains possible to establish 
Figure 3  Antigen-speciﬁ  c T cells exhibit a reduced responsiveness 
to tolerogenic dendritic cells (tolDCs). (A) 105 healthy control (HC) 
and RA CD4 T cells were stimulated with 104 autologous unloaded or 
puriﬁ  ed protein derivative (PPD)-loaded (1 μg/ml) tolDCs or mature DCs 
(matDCs), and proliferation determined at various time points. Data 
are expressed as the mean±SEM of triplicate wells, representative of 
three independent experiments. (B) Mean healthy control (HC) CD4 T 
cell proliferation and cytokine production as a percentage of matDC-
induced T cell responses. HC CD4 T cells (105) were stimulated at a 
10:1 ratio with 104 PPD-loaded tolDCs or matDCs. Cytokine production 
and proliferation were determined on day 6 and 7, respectively. 
Data are expressed as the mean of three independent experiments. 
Mean values for matDC-induced proliferation were 33 642±18807 
cpm, interferon (IFN)γ was 16.9±8.1 ng/ml and interleukin (IL)-17 
was 359.5±328.8 pg/ml. T cell proliferation was determined by [3H]
thymidine incorporation, and cytokine production was quantitated by 
ELISA. *p≤0.05, **p≤0.01, ***p≤0.001 as compared with matDCs 
(two-way analysis of variance (A) and Student t test (B)).
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tolDCs ex vivo for autologous cellular immunotherapy. To our 
knowledge, this is the ﬁ  rst study to demonstrate the generation 
of tolDCs from RA patients.
tolDCs for immunotherapy must be safe, standardised and 
controlled30 31; however, robust and reliable markers are poorly 
deﬁ  ned. Ideally, QC of tolDCs should be based on markers that 
are quickly and readily detectable. Phenotypic identiﬁ  cation 
of tolDCs is most commonly determined relative to other DC 
populations (eg, iDCs and/or matDCs47), which is impractical in 
the cGMP laboratory setting. This study revealed the exclusive 
high-level expression of TLR-2 by tolDCs, a known response 
to glucocorticoids,49–51 making this an ideal marker for QC 
purposes.
Of particular importance in tolDC treatment of inflamma-
tory autoimmune diseases including RA is their stability. We 
therefore investigated the stability of tolDCs to a number 
of known proinflammatory mediators in vitro, as the use of 
maturation-sensitive tolDCs in ongoing inflammatory dis-
ease risks the conversion of tolDCs into matDCs with the 
potential to exacerbate disease.52 This study revealed that 
cGMP-tolDCs, despite differential signalling of MPLA and 
LPS via TLR-4,43 were rendered refractory to further mat-
uration with LPS, a phenomenon previously described for 
LPS as LPS desensitisation.53 tolDCs were also resistant to 
maturation and maintained stable cytokine production in 
response to stimulation with proinflammatory cytokines, 
a process termed DC exhaustion or paralysis.33 54 55 Even 
though the tolDCs described here express high levels of 
TLR-2, PGN, a microbial compound recognised by TLR-2,56 
had only subtle effects on tolDCs. Consistent with our find-
ings, it was recently shown that LPS-activated, Dex-treated 
DCs further challenged with LPS in the absence of Dex were 
phenotypically stable and remained poor producers of TNFα 
and IL-6.57 However, other TLR ligands or proinflammatory 
cytokines were not investigated in that study. In contrast 
with the study of Chamorro et al,51 our study revealed a 
downregulation of TLR-2 expression in the absence of Dex, 
and TLR-2- or TLR-4-mediated challenge of tolDCs failed to 
enhance TLR-2 expression by tolDCs. This may be explained 
by the different TLR-2 ligands used or be due to the different 
protocols used for the establishment of tolDCs. Importantly, 
the cGMP-tolDCs described here, once removed from the 
Figure 4  Tolerogenic dendritic cells (tolDCs) induce T cell hyporesponsiveness. (A) 105 CD4 T cells were primed with the indicated numbers of toxic 
shock syndrome toxin 1 (TSST-1)-loaded (5 ng/ml) autologous tolDCs or mature DCs (matDCs) and proliferation of carboxyﬂ  uorescein succinimidyl 
ester (CFSE+) T cell receptor β-chain variable region 2 (TCR-Vβ2)-stained cells quantitated at day 5. Values represent percentage of cells as a 
percentage of CD4 T cell population. Percentage of Vβ2+ cells in starting CD4 population was 8.9±0.95%. (B) and (C) T cells primed with TSST-1-
loaded (5 ng/ml) tolDCs (Ttol) or matDCs (Tmat) (10:1 ratio) for 6 days were rested with interleukin (IL)-2 (20 IU/ml) for 4 days before CFSE labelling 
and restimulation at a 10:1 ratio with TSST-1-loaded matDCs on day 10. (B) Day 13 T cell proliferation was determined by CFSE dilution. Values 
represent the percentage of proliferating cells. (C) Day 13 intracellular IL-17 and interferon (IFN)γ production was quantitated after 5 h stimulation 
with phorbol myristate acetate (PMA) (50 ng/ml) and ionomycin (1 μg/ml) with brefeldin A (10 μg/ml) added for the ﬁ  nal 4 h. Values represent 
the percentage of cytokine-positive cells as a percentage of the total CD4 T cell population (Ttot). Gates determining positive cells were set using 
equivalent non-PMA/ionomycin-stimulated controls. The percentage of positive cells for IL-17 and IFNγ unstimulated cultures was <1% and <2%, 
respectively. Data shown are representative of two independent experiments.
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appropriate for QC. Potently tolerogenic to autologous T cells, 
these cGMP-tolDCs are highly stable in proinﬂ  ammatory 
environments. tolDCs are a promising novel autologous cellu-
lar therapy for the speciﬁ  c modulation of autoreactive T cells 
in the treatment of RA and other inﬂ  ammatory autoimmune 
diseases.
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tolerising environment of Dex, VitD3 and MPLA, maintained 
a typical semimature phenotype and failed to secrete detect-
able IL-12 in response to a variety of DC maturation fac-
tors, making them well suited for the treatment of ongoing 
inflammatory disease.
A major advantage of tolDC immunotherapy is the poten-
tial for antigen-speciﬁ  c T cell tolerisation, thereby minimising 
the need for sustained non-speciﬁ  c therapies with side effects. 
Our study demonstrates that tolDCs suppress immunogenic 
DC-induced T cell proliferation at a 1:10 tolDC/matDC 
ratio in vitro. Clinical trial of tolDC therapy will ultimately 
reveal tolDC efﬁ   cacy; however, localised administration of 
tolDCs to the arthritic joint will facilitate high tolDC/matDC 
ratios, which may be required for clinical efﬁ  cacy and the re- 
induction of T cell tolerance. Using model antigens, we dem-
onstrate that tolDCs are unaffected by antigen loading and 
mediate antigen-speciﬁ  c hyporesponsiveness without induc-
ing proliferation of ‘bystander’ T cells with low afﬁ  nity for 
the antigen, all of which are important features of targeted 
antigen-speciﬁ  c therapy. The pathogenic autoantigen in RA 
is unknown, however; future studies will reveal the toleris-
ing effects of tolDCs to non-characterised RA autoantigen(s) 
  present within   synovial ﬂ  uid.58–60
This study describes the development of clinical-grade 
tolDCs established using a simple and robust protocol. These 
tolDCs are classically semimature with an anti-inﬂ  ammatory 
phenotype and exhibit high-level expression of TLR-2, highly 
Figure 5  Tolerogenic dendritic cells (tolDCs) suppress mature DC 
(matDC)-induced T cell proliferation, interferon (IFN)γ and interleukin 
(IL)-17. (A) Representative graph showing control CD4 T cell responses 
to puriﬁ  ed protein derivative (PPD)-loaded DCs (1 μg/ml). CD4 T cells 
(105) were cocultured at a 10:1 ratio with tolDCs or matDCs alone 
or matDCs with an equivalent number of tolDCs or matDCs as a cell 
number control (1:1 ratio; 104) or 10-fold fewer tolDCs than matDCs 
(1:10 ratio; 103). Proliferation was quantitated at days 3, 5 and 7 by 
[3H]thymidine incorporation. The graph is representative of four 
independent experiments. (B) Mean IFNγ and IL-17 cytokine production 
relative to matDCs. CD4 T cells (105) were stimulated with autologous 
PPD-loaded DCs as in (A). Cytokine production was quantitated on 
day 6 by ELISA. Data are expressed as the mean±SEM from three 
independent experiments. *p≤0.05, **p≤0.01, ***p≤0.001 as 
compared with matDCs (two-way analysis of variance (A) and analysis 
of variance (B)).
Figure 6   Tolerogenic dendritic cells (tolDCs) have a highly stable 
semimature, anti-inﬂ  ammatory phenotype. Phenotypic stability of tolDCs 
and mature DCs (matDCs) was determined in response to inﬂ  ammatory 
stimuli. tolDCs or matDCs were washed and recultured in the absence 
of tolerising factors including dexamethasone and vitamin D3 for 24 h. 
Cultures were either unstimulated (US) or stimulated with a cocktail 
of proinﬂ  ammatory cytokines (cyt) containing interleukin (IL)-1β, IL-6, 
tumour necrosis factor (TNF)α (all 10 ng/ml) and interferon (IFN)γ (1000 
U/ml), lipopolysaccharide (LPS) (0.1 μg/ml) or peptidoglycan (PGN) 
(10 μg/ml). (A) DCs were analysed for cell surface phenotype by ﬂ  ow 
cytometry. Plots show mean geometric mean ﬂ  uorescence intensity 
(GMFI) of DC-maturation markers of tolDCs and matDCs. Data are 
expressed as the mean GMFI±SEM of at least four independent donors. 
(B) tolDCs and matDCs (105/well) were activated via CD40 by culture 
with an equivalent number of the J588L-CD40L-expressing cell line in 
the presence or absence of inﬂ  ammatory mediators and supernatants 
collected after 24 h for analysis by ELISA. <d, below limits of detection 
(30 pg/ml for IL-12 ELISA) *p<0.05, **p≤0.01 (analysis of variance). 
MHC, major histocompatibility complex; TLR-2, toll-like receptor 2.
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